Home » Stocks » NCNA

NuCana PLC (NCNA)

Stock Price: $2.12 USD -0.02 (-0.93%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
Market Cap 109.95M
Revenue (ttm) n/a
Net Income (ttm) -49.97M
Shares Out 52.16M
EPS (ttm) -1.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $2.12
Previous Close $2.14
Change ($) -0.02
Change (%) -0.93%
Day's Open 2.15
Day's Range 2.08 - 2.15
Day's Volume 393,580
52-Week Range 2.03 - 7.83

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Presented Encouraging Clinical Data at ASCO-GI and AACR

2 months ago - GlobeNewsWire

EDINBURGH, United Kingdom, April 28, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one...

3 months ago - GlobeNewsWire

EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2...

3 months ago - GlobeNewsWire

Presented Encouraging Clinical Data for NUC-3373 and NUC-7738

4 months ago - GlobeNewsWire

Find out what led to the biotech industry's biggest gains.

Other stocks mentioned: ALDX, LXRX
6 months ago - The Motley Fool

Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy

6 months ago - GlobeNewsWire

NuCana (NCNA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

Pharmaceutical Executive Brings a Wealth of Experience to NuCana's Board of Directors

7 months ago - GlobeNewsWire

Acelarin plus Cisplatin's High Objective Response Rate and Favorable Safety Profile Confirmed

8 months ago - GlobeNewsWire

Completed Successful $ 8 0 million Public Offering

8 months ago - GlobeNewsWire

EDINBURGH, United Kingdom, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present a...

8 months ago - GlobeNewsWire

EDINBURGH, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present a...

8 months ago - GlobeNewsWire

NuCana (NCNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

8 months ago - Zacks Investment Research

Abingworth Makes Significant Investment in NuCana’s Recent $80 million Public Offering Abingworth Makes Significant Investment in NuCana’s Recent $80 million Public Offering

9 months ago - GlobeNewsWire

NuCana (NCNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

Encouraging Efficacy Signals Observed in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer in the Phase Ib Study of NUC-3373 (NuTide:302)

10 months ago - GlobeNewsWire

EDINBURGH, United Kingdom, Sept. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, ann...

10 months ago - GlobeNewsWire

EDINBURGH, United Kingdom, Sept. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, ann...

10 months ago - GlobeNewsWire

EDINBURGH, United Kingdom, Sept. 16, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, ann...

10 months ago - GlobeNewsWire

EDINBURGH, United Kingdom, Aug. 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2020 and provided an update on its broad clinic...

11 months ago - GlobeNewsWire

NuCana (NCNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

11 months ago - Zacks Investment Research

NuCana (NCNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor of NuCana

1 year ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for May 28th

Other stocks mentioned: AAWW, AXU, GMDA
1 year ago - Zacks Investment Research

The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.

Other stocks mentioned: CYAD, DXCM, HOLX, TDOC
1 year ago - Zacks Investment Research

Clinical Studies Re-Opened to New Patient Enrollment Following Temporary Pause Due to COVID-19 Pandemic

1 year ago - GlobeNewsWire

EDINBURGH, United Kingdom, May 18, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in multiple clinical studies following the temporary paus...

1 year ago - GlobeNewsWire

EDINBURGH, U.K., May 05, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in NuTide:121, its ongoing global Phase III study of Acelarin (NUC-...

1 year ago - GlobeNewsWire

EDINBURGH, United Kingdom, April 02, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) has been closely monitoring the potential impact of the COVID-19 pandemic on its operations and announced today ...

1 year ago - GlobeNewsWire

Confirmed Complete Response and Two Partial Responses Achieved in Heavily Pre-treated Population

1 year ago - GlobeNewsWire

EDINBURGH, United Kingdom, March 04, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has issued a...

1 year ago - GlobeNewsWire

We expect NuCana (NCNA) to provide updates on its pipeline when it releases fourth-quarter results.

1 year ago - Zacks Investment Research

Global NuTide:121 Study Is Enrolling up to 828 Patients and Comparing Acelarin plus Cisplatin to Gemcitabine plus Cisplatin

1 year ago - GlobeNewsWire

NUC-3373: Favorable Pharmacokinetic Profile Demonstrated

1 year ago - GlobeNewsWire

Global NuTide:121 Study will Enroll up to 828 Patients and Compare Acelarin plus Cisplatin to Gemcitabine plus Cisplatin

1 year ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in NuCana plc (NCNA).

1 year ago - Zacks Investment Research

EDINBURGH, United Kingdom, Aug. 29, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present...

1 year ago - GlobeNewsWire

EDINBURGH, United Kingdom, Aug. 27, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host on...

1 year ago - GlobeNewsWire

Numerous Clinical Data Announcements and Study Initiations Expected in 2019

1 year ago - GlobeNewsWire

NuCana (NCNA) suspends patient enrollment in the phase III study on Acelarin, currently evaluated for treating patients with metastatic pancreatic cancer, who were unfit for combination chemotherapy.

1 year ago - Zacks Investment Research

Shares of NuCana Plc fell 21% on Tuesday after the company announced it had suspended the enrollment of new patients in a late-stage trial of a pancreatic cancer drug.

1 year ago - Market Watch

Imbalances in Prognostic Factors May Have Impacted Analysis

1 year ago - GlobeNewsWire

Falling Knives are companies whose share prices have fallen more than 59% over the past year, generating the interest of investors as they can make huge gains if they bounce back.

Other stocks mentioned: GLYC
1 year ago - GuruFocus

NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.

2 years ago - Zacks Investment Research

The FDA confers an orphan drug designation on NuCana's (NCNA) pipeline candidate, Acelarin, for treating patients with biliary tract cancer

2 years ago - Zacks Investment Research

NCNA’s ProTide technology has been used to develop drugs like Sovaldi and Genvoya.

2 years ago - Seeking Alpha

About NCNA

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian can... [Read more...]

Industry
Biotechnology
IPO Date
Sep 28, 2017
CEO
Hugh Griffith
Employees
27
Stock Exchange
NASDAQ
Ticker Symbol
NCNA
Full Company Profile

Financial Performance

Financial numbers in millions GBP.
Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for NuCana stock is "Strong Buy." The 12-month stock price forecast is 1,144.93, which is an increase of 53,906.13% from the latest price.

Price Target
$1,144.93
(53,906.13% upside)
Analyst Consensus: Strong Buy